ezetimibe Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperlipidaemics, acyl CoA: cholesterol acyltransferase (ACAT) inhibitors 1125 163222-33-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • SCH58235
  • SCH-58235
  • ezetimib
  • ezetimibe
  • ezedoc
  • ezentia
  • ezetrol
  • zetia
An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.
  • Molecular weight: 409.43
  • Formula: C24H21F2NO3
  • CLOGP: 3.96
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 2
  • TPSA: 60.77
  • ALOGS: -4.68
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.35 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Oct. 25, 2002 FDA MSD INTL GMBH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myalgia 752.97 10.17 850 58167 122238 46504807
Rhabdomyolysis 603.84 10.17 467 58550 41442 46585603
Blood creatine phosphokinase increased 284.54 10.17 254 58763 27470 46599575
Low density lipoprotein increased 186.52 10.17 108 58909 5892 46621153
Myopathy 110.70 10.17 91 58926 8790 46618255
Muscle spasms 107.32 10.17 371 58646 122742 46504303
Muscular weakness 89.09 10.17 287 58730 91557 46535488
Toxicity to various agents 86.63 10.17 84 58933 211682 46415363
Drug ineffective 85.93 10.17 505 58512 677333 45949712
Death 83.67 10.17 188 58829 335360 46291685
Blood cholesterol increased 78.43 10.17 163 58854 39850 46587195
Pain in extremity 78.20 10.17 577 58440 258103 46368942
Contraindicated product administered 78.20 10.17 6 59011 79941 46547104
Completed suicide 76.14 10.17 45 58972 145875 46481170
Angina pectoris 74.86 10.17 127 58890 26648 46600397
Maternal exposure during pregnancy 74.25 10.17 19 58998 102530 46524515
Rheumatoid arthritis 71.61 10.17 121 58896 240094 46386951
Pancreatitis acute 70.90 10.17 119 58898 24753 46602292
Coronary artery disease 70.29 10.17 141 58876 33611 46593434
Liver function test abnormal 68.39 10.17 169 58848 46318 46580727
Myocardial infarction 68.30 10.17 274 58743 97254 46529791
Pancreatitis 65.66 10.17 160 58857 43467 46583578
Acute kidney injury 59.10 10.17 504 58513 235351 46391694
Exposure during pregnancy 56.96 10.17 33 58984 108179 46518866
Off label use 56.86 10.17 267 58750 379574 46247471
Synovitis 55.92 10.17 6 59011 61069 46565976
Coronary artery occlusion 54.57 10.17 59 58958 8043 46619002
Acute coronary syndrome 53.04 10.17 65 58952 10139 46616906
Hyperlipidaemia 51.90 10.17 88 58929 18451 46608594
High density lipoprotein decreased 49.75 10.17 30 58987 1764 46625281
Drug abuse 49.38 10.17 10 59007 63398 46563647
Intentional overdose 49.03 10.17 11 59006 64933 46562112
Aspartate aminotransferase increased 47.99 10.17 212 58805 78488 46548557
Arterial stenosis 47.85 10.17 21 58996 630 46626415
Alanine aminotransferase increased 44.26 10.17 225 58792 88226 46538819
Infusion related reaction 43.88 10.17 38 58979 101170 46525875
Blood glucose increased 41.66 10.17 191 58826 71822 46555223
Polymyositis 39.68 10.17 25 58992 1590 46625455
Febrile neutropenia 39.26 10.17 37 58980 94590 46532455
Treatment failure 39.09 10.17 36 58981 93051 46533994
Flatulence 38.32 10.17 101 58916 28777 46598268
Vascular stent stenosis 37.86 10.17 17 59000 539 46626506
Carotid arteriosclerosis 36.87 10.17 20 58997 960 46626085
Blood triglycerides increased 35.76 10.17 58 58959 11725 46615320
Coombs positive haemolytic anaemia 33.34 10.17 14 59003 376 46626669
Product use issue 32.69 10.17 43 58974 94601 46532444
Antinuclear antibody negative 32.44 10.17 12 59005 228 46626817
Arterial occlusive disease 32.38 10.17 35 58982 4769 46622276
Dizziness 32.05 10.17 606 58411 339808 46287237
Lipids increased 30.94 10.17 18 58999 990 46626055
Neutropenia 30.35 10.17 87 58930 143117 46483928
Muscle disorder 30.26 10.17 32 58985 4254 46622791
Myositis 29.76 10.17 43 58974 7861 46619184
Pyrexia 29.19 10.17 291 58726 348511 46278534
Sensorimotor disorder 29.05 10.17 13 59004 409 46626636
Herpes simplex reactivation 27.72 10.17 12 59005 348 46626697
Cardiac failure congestive 27.24 10.17 204 58813 91546 46535499
Disease progression 27.14 10.17 46 58971 91254 46535791
Hyper IgE syndrome 25.97 10.17 10 59007 213 46626832
Immune-mediated myositis 24.58 10.17 15 59002 901 46626144
Device expulsion 24.47 10.17 3 59014 27539 46599506
Body tinea 24.30 10.17 15 59002 920 46626125
Inhibitory drug interaction 23.94 10.17 20 58997 1975 46625070
Hypoglycaemia 23.59 10.17 133 58884 54216 46572829
Coma acidotic 23.01 10.17 8 59009 126 46626919
Palpitations 22.97 10.17 202 58815 95057 46531988
Asthenia 22.80 10.17 534 58483 310541 46316504
Cerebrovascular accident 22.70 10.17 211 58806 100828 46526217
Glucose tolerance impaired 22.29 10.17 29 58988 4802 46622243
Infection 22.29 10.17 90 58927 133502 46493543
Chest pain 22.09 10.17 329 58688 175995 46451050
Sepsis 21.84 10.17 93 58924 135921 46491124
Gangrene 21.38 10.17 28 58989 4667 46622378
Angina unstable 21.35 10.17 36 58981 7512 46619533
Muscle rupture 21.33 10.17 19 58998 2046 46624999
Coronary artery thrombosis 21.29 10.17 15 59002 1150 46625895
Dyslipidaemia 20.65 10.17 30 58987 5510 46621535
Abortion spontaneous 20.65 10.17 15 59002 43631 46583414
Hyperkalaemia 20.64 10.17 122 58895 50587 46576458
Transient ischaemic attack 20.49 10.17 93 58924 34810 46592235
Gait disturbance 20.17 10.17 276 58741 144987 46482058
Back pain 20.09 10.17 375 58642 209664 46417381
Pancytopenia 20.04 10.17 49 58968 85009 46542036
Biliary fibrosis 19.93 10.17 4 59013 4 46627041
Copper metabolism disorder 19.93 10.17 4 59013 4 46627041
Wound 19.88 10.17 15 59002 42787 46584258
Pregnancy 19.68 10.17 5 59012 27132 46599913
Gastritis haemorrhagic 19.55 10.17 15 59002 1311 46625734
Depressed level of consciousness 19.26 10.17 19 58998 47550 46579495
Obstructive pancreatitis 19.08 10.17 8 59009 214 46626831
Cardiac valve disease 18.51 10.17 24 58993 3960 46623085
Toxic epidermal necrolysis 18.45 10.17 3 59014 22275 46604770
Diabetic neuropathy 17.88 10.17 23 58994 3766 46623279
Therapeutic product effect decreased 17.62 10.17 50 58967 82551 46544494
Paresis 17.60 10.17 17 59000 2029 46625016
Blood glucose decreased 17.36 10.17 58 58959 18834 46608211
Fall 17.27 10.17 541 58476 328556 46298489
Therapy cessation 17.18 10.17 73 58944 26556 46600489
Lipids abnormal 17.16 10.17 8 59009 277 46626768
Aortic stenosis 16.73 10.17 24 58993 4358 46622687
Congenital musculoskeletal anomaly 16.48 10.17 9 59008 438 46626607
Low density lipoprotein decreased 16.20 10.17 7 59010 202 46626843
Ischaemic cardiomyopathy 15.84 10.17 18 58999 2592 46624453
Abnormal dreams 15.78 10.17 38 58979 10241 46616804
Platelet count decreased 15.68 10.17 69 58948 99955 46527090
Disease risk factor 15.63 10.17 5 59012 60 46626985
Chromaturia 15.51 10.17 48 58969 14971 46612074
Troponin increased 15.49 10.17 32 58985 7784 46619261
Glossodynia 15.48 10.17 20 58997 44353 46582692
Coronary artery stenosis 15.40 10.17 24 58993 4689 46622356
Foetal exposure during pregnancy 15.30 10.17 10 59007 30737 46596308
Seizure 15.27 10.17 92 58925 122962 46504083
Hepatic cyst 15.20 10.17 24 58993 4742 46622303
Overdose 15.00 10.17 72 58945 101907 46525138
Joint swelling 14.94 10.17 136 58881 165937 46461108
Septic shock 14.73 10.17 32 58985 57861 46569184
Spleen congestion 14.58 10.17 6 59011 153 46626892
Pericarditis 14.55 10.17 6 59011 23921 46603124
Acute myocardial infarction 14.43 10.17 79 58938 31845 46595200
Intentional product use issue 14.42 10.17 28 58989 52752 46574293
Muscle discomfort 14.25 10.17 5 59012 81 46626964
Impaired quality of life 14.24 10.17 19 58998 3223 46623822
Psoriatic arthropathy 14.19 10.17 15 59002 36364 46590681
Anembryonic gestation 14.18 10.17 9 59008 580 46626465
Euglycaemic diabetic ketoacidosis 14.14 10.17 15 59002 2001 46625044
Lactic acidosis 14.07 10.17 82 58935 33827 46593218
Helicobacter gastritis 14.06 10.17 13 59004 1469 46625576
Hospitalisation 13.79 10.17 38 58979 63347 46563698
Pancreatitis relapsing 13.57 10.17 9 59008 625 46626420
Lower respiratory tract infection 13.56 10.17 31 58986 55058 46571987
Chest discomfort 13.55 10.17 174 58843 90095 46536950
Lipoprotein (a) increased 13.53 10.17 4 59013 36 46627009
Blood cholesterol decreased 13.52 10.17 8 59009 454 46626591
C-reactive protein abnormal 13.48 10.17 5 59012 21265 46605780
Gastric disorder 13.39 10.17 68 58949 26637 46600408
Glycosylated haemoglobin increased 13.38 10.17 37 58980 10839 46616206
Blood creatine phosphokinase MM increased 13.34 10.17 4 59013 38 46627007
Malignant neoplasm progression 13.34 10.17 40 58977 64886 46562159
Gingival oedema 13.28 10.17 5 59012 100 46626945
Infection susceptibility increased 13.18 10.17 15 59002 2164 46624881
Peripheral artery haematoma 13.16 10.17 4 59013 40 46627005
Pruritus 13.12 10.17 400 58617 241952 46385093
Hypocholesterolaemia 13.10 10.17 5 59012 104 46626941
Nephropathy 13.02 10.17 23 58994 4982 46622063
White blood cell count decreased 12.85 10.17 86 58931 112145 46514900
Low density lipoprotein abnormal 12.79 10.17 5 59012 111 46626934
Gastrooesophageal reflux disease 12.76 10.17 147 58870 74197 46552848
Suicide attempt 12.73 10.17 32 58985 55004 46572041
Blood cholesterol abnormal 12.64 10.17 15 59002 2262 46624783
Cell death 12.58 10.17 15 59002 2273 46624772
Hypotrichosis 12.55 10.17 5 59012 117 46626928
Pleural effusion 12.53 10.17 58 58959 82894 46544151
Myoglobin blood increased 12.48 10.17 12 59005 1424 46625621
Total cholesterol/HDL ratio decreased 12.21 10.17 3 59014 12 46627033
Mucosal inflammation 12.17 10.17 19 58998 38957 46588088
Non-high-density lipoprotein cholesterol increased 12.17 10.17 5 59012 127 46626918
Hypersensitivity pneumonitis 12.14 10.17 15 59002 2358 46624687
Nasal cyst 12.14 10.17 4 59013 53 46626992
Complex regional pain syndrome 12.12 10.17 14 59003 2052 46624993
Restrictive pulmonary disease 12.11 10.17 11 59006 1215 46625830
Drug dependence 12.08 10.17 5 59012 19896 46607149
Hepatic enzyme increased 12 10.17 157 58860 81630 46545415
Product use in unapproved indication 12.00 10.17 66 58951 90207 46536838
Vitamin D deficiency 11.89 10.17 36 58981 11098 46615947
Language disorder 11.88 10.17 12 59005 1511 46625534
Ear haemorrhage 11.79 10.17 11 59006 1257 46625788
Pulmonary haematoma 11.75 10.17 4 59013 59 46626986
Hypertension 11.69 10.17 328 58689 196028 46431017
Pneumonia 11.59 10.17 375 58642 375945 46251100
Intervertebral disc degeneration 11.57 10.17 40 58977 13212 46613833
Acquired epidermolysis bullosa 11.56 10.17 4 59013 62 46626983
Systemic lupus erythematosus 11.45 10.17 43 58974 65137 46561908
Abdominal pain upper 11.41 10.17 252 58765 145053 46481992
C-reactive protein increased 11.40 10.17 37 58980 58553 46568492
Condition aggravated 11.34 10.17 230 58787 244822 46382223
Cataract 11.30 10.17 97 58920 45318 46581727
Pneumonia aspiration 11.28 10.17 14 59003 31591 46595454
Muscle atrophy 11.28 10.17 24 58993 5960 46621085
Small intestinal haemorrhage 11.21 10.17 13 59004 1913 46625132
Autoimmune hepatitis 11.05 10.17 28 58989 7786 46619259
Bladder irritation 11.01 10.17 5 59012 163 46626882
Intestinal transit time abnormal 10.96 10.17 4 59013 73 46626972
Multiple sclerosis relapse 10.95 10.17 23 58994 42102 46584943
Respiratory disorder 10.94 10.17 11 59006 27289 46599756
Depression 10.93 10.17 287 58730 169817 46457228
Somnolence 10.91 10.17 136 58881 156385 46470660
Encephalopathy 10.85 10.17 16 59001 33573 46593472
Antiphospholipid syndrome 10.72 10.17 12 59005 1700 46625345
Oedema peripheral 10.71 10.17 271 58746 159435 46467610
Sedation 10.67 10.17 8 59009 22902 46604143
Peroneal nerve palsy 10.64 10.17 19 58998 4149 46622896
Cerebellar syndrome 10.44 10.17 17 59000 3448 46623597
Total cholesterol/HDL ratio increased 10.40 10.17 4 59013 85 46626960
Ascites 10.35 10.17 19 58998 36565 46590480
Necrotising myositis 10.31 10.17 6 59011 330 46626715
Premature baby 10.29 10.17 5 59012 18107 46608938
Neutrophil count decreased 10.24 10.17 25 58992 43401 46583644
Type 2 diabetes mellitus 10.24 10.17 51 58966 19824 46607221
Clostridium difficile infection 10.19 10.17 10 59007 25093 46601952

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Myalgia 937.70 10.65 910 53863 75757 29821948
Blood creatine phosphokinase increased 493.27 10.65 498 54275 43350 29854355
Rhabdomyolysis 465.54 10.65 577 54196 63003 29834702
Myopathy 305.56 10.65 208 54565 10378 29887327
Low density lipoprotein increased 195.17 10.65 110 54663 3906 29893799
Death 120.22 10.65 301 54472 356982 29540723
Blood cholesterol increased 106.62 10.65 143 54630 16827 29880878
Toxicity to various agents 105.73 10.65 101 54672 177082 29720623
Muscular weakness 105.55 10.65 305 54468 63340 29834365
Drug abuse 100.70 10.65 15 54758 82057 29815648
Myocardial infarction 97.43 10.65 471 54302 125154 29772551
Muscle spasms 96.43 10.65 299 54474 64539 29833166
Coronary artery disease 91.02 10.65 247 54526 49465 29848240
Low density lipoprotein decreased 89.10 10.65 41 54732 940 29896765
Angina pectoris 84.95 10.65 175 54598 29343 29868362
Immune-mediated myositis 81.46 10.65 42 54731 1243 29896462
Venous pressure jugular increased 75.03 10.65 33 54740 678 29897027
High density lipoprotein decreased 71.72 10.65 54 54719 3156 29894549
Febrile neutropenia 69.38 10.65 56 54717 106637 29791068
Completed suicide 66.23 10.65 51 54722 99441 29798264
Pancreatitis 60.56 10.65 175 54598 36315 29861390
Off label use 58.52 10.65 246 54527 249044 29648661
Myositis 52.68 10.65 79 54694 10298 29887407
Neutropenia 52.38 10.65 97 54676 128443 29769262
Foetal exposure during pregnancy 52.16 10.65 4 54769 36867 29860838
Hepatic enzyme increased 50.24 10.65 155 54618 33339 29864366
Drug interaction 48.60 10.65 568 54205 199000 29698705
Pancreatitis acute 48.33 10.65 129 54644 25566 29872139
Pneumonia 48.32 10.65 386 54387 333920 29563785
Dizziness 44.05 10.65 547 54226 194362 29703343
Blood triglycerides increased 43.77 10.65 86 54687 13931 29883774
Suicide attempt 42.12 10.65 8 54765 36689 29861016
Blood cholesterol decreased 40.55 10.65 24 54749 935 29896770
Liver function test abnormal 39.89 10.65 136 54637 30814 29866891
Asthenia 39.76 10.65 596 54177 220694 29677011
Type IIa hyperlipidaemia 37.96 10.65 11 54762 60 29897645
Chest pain 37.14 10.65 353 54420 117274 29780431
Treatment failure 36.87 10.65 9 54764 34670 29863035
Acute kidney injury 36.61 10.65 703 54070 273139 29624566
Intentional overdose 36.58 10.65 15 54758 41466 29856239
Chromaturia 36.16 10.65 79 54694 13786 29883919
Pain in extremity 34.41 10.65 330 54443 109891 29787814
Pyrexia 34.24 10.65 359 54414 294130 29603575
Erectile dysfunction 34.16 10.65 91 54682 18011 29879694
Cutaneous lupus erythematosus 33.46 10.65 18 54755 582 29897123
Acute coronary syndrome 32.78 10.65 75 54698 13498 29884207
Malignant neoplasm progression 32.68 10.65 51 54722 72236 29825469
Erythromelalgia 32.05 10.65 9 54764 43 29897662
Dissociation 31.98 10.65 22 54751 1115 29896590
Coronary artery occlusion 31.91 10.65 66 54707 11091 29886614
Amyotrophic lateral sclerosis 31.79 10.65 21 54752 995 29896710
Disease progression 31.00 10.65 62 54711 79812 29817893
Muscle disorder 30.65 10.65 29 54744 2323 29895382
Septic shock 30.58 10.65 43 54730 63564 29834141
Pancytopenia 30.52 10.65 69 54704 84983 29812722
Alanine aminotransferase increased 30.30 10.65 236 54537 74040 29823665
Dyspnoea exertional 29.68 10.65 136 54637 35294 29862411
Muscle rupture 29.27 10.65 27 54746 2094 29895611
Cardiac failure congestive 28.99 10.65 258 54515 84149 29813556
Glycogen storage disease type V 28.88 10.65 8 54765 36 29897669
Sepsis 28.67 10.65 154 54619 146241 29751464
Cardio-respiratory arrest 28.29 10.65 38 54735 57268 29840437
Left ventricular dysfunction 27.95 10.65 54 54719 8637 29889068
Hospitalisation 27.87 10.65 24 54749 44295 29853410
Ischaemic cardiomyopathy 27.86 10.65 45 54728 6252 29891453
Aspartate aminotransferase increased 27.82 10.65 205 54568 63217 29834488
Arthralgia 27.63 10.65 374 54399 135417 29762288
Bone marrow failure 27.54 10.65 10 54763 29775 29867930
Overdose 27.44 10.65 72 54701 84265 29813440
Product use in unapproved indication 27.08 10.65 59 54714 73634 29824071
Angina unstable 26.45 10.65 65 54708 12245 29885460
Exercise lack of 26.43 10.65 9 54764 89 29897616
Muscle atrophy 26.18 10.65 45 54728 6579 29891126
Drug dependence 25.85 10.65 4 54769 21291 29876414
Cytomegalovirus infection 25.45 10.65 6 54767 23668 29874037
Stent placement 24.78 10.65 36 54737 4560 29893145
Pemphigoid 24.49 10.65 47 54726 7481 29890224
Haematocrit increased 24.43 10.65 22 54751 1654 29896051
Rheumatoid arthritis 23.91 10.65 24 54749 41173 29856532
Plasma cell myeloma 23.89 10.65 38 54735 53424 29844281
Muscle injury 23.84 10.65 19 54754 1208 29896497
Intentional product use issue 23.82 10.65 19 54754 36421 29861284
Pancreatic neoplasm 23.37 10.65 17 54756 942 29896763
Delirium 23.20 10.65 24 54749 40607 29857098
Myasthenia gravis 23.19 10.65 28 54745 2964 29894741
Leukopenia 23.18 10.65 42 54731 56117 29841588
Hypercholesterolaemia 23.00 10.65 46 54727 7546 29890159
Oedema peripheral 22.98 10.65 295 54478 105537 29792168
Left atrial dilatation 22.97 10.65 22 54751 1789 29895916
Mucosal inflammation 22.43 10.65 14 54759 30480 29867225
Cardiac disorder 22.33 10.65 137 54636 39756 29857949
Food aversion 22.29 10.65 11 54762 296 29897409
White blood cell count decreased 22.08 10.65 79 54694 83868 29813837
Ascites 21.92 10.65 20 54753 35901 29861804
Cardiac murmur 21.42 10.65 42 54731 6792 29890913
Faeces pale 20.77 10.65 19 54754 1458 29896247
Low density lipoprotein abnormal 20.37 10.65 10 54763 266 29897439
Dyslipidaemia 20.18 10.65 37 54736 5690 29892015
Hypovolaemia 20.17 10.65 47 54726 8558 29889147
Multiple organ dysfunction syndrome 20.04 10.65 55 54718 63432 29834273
Mucosal dryness 19.83 10.65 16 54757 1035 29896670
Hepatitis cholestatic 19.56 10.65 44 54729 7828 29889877
Infection 19.53 10.65 75 54698 77999 29819706
Respiratory arrest 19.44 10.65 15 54758 29243 29868462
Agitation 19.28 10.65 44 54729 54029 29843676
Necrotising myositis 19.22 10.65 11 54762 402 29897303
Laryngeal discomfort 19.16 10.65 8 54765 144 29897561
Self esteem decreased 18.84 10.65 12 54761 534 29897171
Orthostatic hypotension 18.58 10.65 90 54683 23889 29873816
Seizure 18.49 10.65 105 54668 98370 29799335
Toxic epidermal necrolysis 18.41 10.65 5 54768 17935 29879770
Candida infection 18.39 10.65 3 54770 15359 29882346
Tendon rupture 18.14 10.65 40 54733 7024 29890681
Phaeochromocytoma malignant 18.12 10.65 6 54767 54 29897651
Respiratory failure 18.00 10.65 109 54664 100533 29797172
Neck pain 17.99 10.65 81 54692 20863 29876842
Platelet count decreased 17.92 10.65 117 54656 106012 29791693
Coeliac disease 17.71 10.65 12 54761 593 29897112
Blood creatine phosphokinase decreased 17.50 10.65 11 54762 478 29897227
Depressed level of consciousness 17.23 10.65 27 54746 38195 29859510
Myocardial ischaemia 17.21 10.65 70 54703 17247 29880458
Aldolase increased 17.13 10.65 6 54767 65 29897640
Paraesthesia 17.09 10.65 163 54610 54164 29843541
Exercise tolerance decreased 16.54 10.65 27 54746 3785 29893920
Coronary artery stenosis 16.51 10.65 45 54728 9025 29888680
Neutrophil count decreased 16.42 10.65 33 54740 42421 29855284
Suspected suicide attempt 16.04 10.65 7 54766 141 29897564
Haemoglobin increased 16.04 10.65 23 54750 2879 29894826
Pericardial haemorrhage 15.94 10.65 23 54750 2895 29894810
Pneumonia aspiration 15.81 10.65 28 54745 37752 29859953
Syncope 15.70 10.65 230 54543 84673 29813032
Total cholesterol/HDL ratio increased 15.69 10.65 7 54766 149 29897556
Influenza like illness 15.65 10.65 90 54683 25515 29872190
Polymyositis 15.54 10.65 16 54757 1420 29896285
Flatulence 15.48 10.65 70 54703 18059 29879646
Transaminases abnormal 15.48 10.65 8 54765 238 29897467
Spinal stenosis 15.29 10.65 28 54745 4301 29893404
Back pain 15.24 10.65 268 54505 102328 29795377
Arteriosclerosis 15.19 10.65 49 54724 10784 29886921
Lymphocyte count decreased 15.08 10.65 8 54765 19047 29878658
Autoimmune hepatitis 14.81 10.65 25 54748 3602 29894103
Acute myocardial infarction 14.80 10.65 155 54618 52784 29844921
Lipase increased 14.76 10.65 42 54731 8634 29889071
Drug withdrawal syndrome 14.70 10.65 9 54764 19800 29877905
Atrial fibrillation 14.51 10.65 278 54495 107846 29789859
Tumour lysis syndrome 14.38 10.65 3 54770 12882 29884823
Sedation 14.30 10.65 6 54767 16367 29881338
Tachycardia 14.18 10.65 78 54695 73661 29824044
Dyschromatopsia 14.06 10.65 8 54765 289 29897416
Dyspnoea 14.03 10.65 744 54029 332551 29565154
Gait disturbance 13.99 10.65 203 54570 74574 29823131
Bronchopneumopathy 13.94 10.65 9 54764 410 29897295
Thrombocytopenia 13.92 10.65 172 54601 136872 29760833
Hepatitis E virus test positive 13.63 10.65 4 54769 23 29897682
Stomatitis 13.56 10.65 30 54743 37249 29860456
Restrictive pulmonary disease 13.44 10.65 13 54760 1070 29896635
Blood creatine phosphokinase 13.39 10.65 5 54768 66 29897639
Fatigue 13.32 10.65 715 54058 319958 29577747
International normalised ratio abnormal 13.27 10.65 22 54751 3124 29894581
Autoimmune myositis 13.21 10.65 4 54769 26 29897679
Tumour invasion 13.00 10.65 8 54765 335 29897370
Ureteric cancer recurrent 12.72 10.65 4 54769 30 29897675
Abulia 12.66 10.65 9 54764 481 29897224
Aortic embolus 12.63 10.65 3 54770 6 29897699
Pleural neoplasm 12.61 10.65 4 54769 31 29897674
Intentional product misuse 12.53 10.65 28 54745 34639 29863066
Muscle fatigue 12.40 10.65 13 54760 1178 29896527
Prostatic specific antigen increased 12.31 10.65 49 54724 11955 29885750
Blood glucose increased 12.29 10.65 169 54604 61361 29836344
Muscle discomfort 12.28 10.65 4 54769 34 29897671
Neoplasm progression 12.28 10.65 9 54764 18014 29879691
Gastric dilatation 12.20 10.65 9 54764 510 29897195
Infusion related reaction 12.17 10.65 36 54737 40528 29857177
Hypercapnic coma 12.11 10.65 6 54767 163 29897542
C-reactive protein increased 12.04 10.65 40 54733 43433 29854272
Peritonitis bacterial 12.00 10.65 3 54770 11375 29886330
Clostridium difficile infection 11.95 10.65 7 54766 15776 29881929
Obstructive pancreatitis 11.89 10.65 8 54765 391 29897314
Gamma-glutamyltransferase increased 11.81 10.65 93 54680 29257 29868448
Chronic cutaneous lupus erythematosus 11.80 10.65 4 54769 39 29897666
Peritonitis 11.78 10.65 13 54760 21362 29876343
Disseminated intravascular coagulation 11.66 10.65 14 54759 22157 29875548
Glycosylated haemoglobin increased 11.61 10.65 41 54732 9450 29888255
Status epilepticus 11.52 10.65 3 54770 11069 29886636
Pancreatic carcinoma 11.49 10.65 36 54737 7801 29889904
Hypokalaemia 11.43 10.65 50 54723 50142 29847563
Retroperitoneal fibrosis 11.37 10.65 7 54766 293 29897412
Heart valve incompetence 11.37 10.65 12 54761 1096 29896609
Iron binding capacity total increased 11.37 10.65 4 54769 44 29897661
JC polyomavirus test positive 11.23 10.65 9 54764 577 29897128
Erythrasma 11.05 10.65 4 54769 48 29897657
Nasal neoplasm 10.97 10.65 5 54768 112 29897593
Pleural effusion 10.86 10.65 85 54688 73981 29823724
Dyspnoea at rest 10.69 10.65 18 54755 2588 29895117

Pharmacologic Action:

SourceCodeDescription
ATC C10AX09 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
Other lipid modifying agents
ATC C10BA02 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
Combinations of various lipid modifying agents
ATC C10BA05 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
Combinations of various lipid modifying agents
ATC C10BA06 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
Combinations of various lipid modifying agents
ATC C10BA10 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
Combinations of various lipid modifying agents
FDA PE N0000008553 Decreased Cholesterol Absorption
MeSH PA D000924 Anticholesteremic Agents
MeSH PA D000963 Antimetabolites
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D057847 Lipid Regulating Agents
FDA EPC N0000175911 Dietary Cholesterol Absorption Inhibitor
CHEBI has role CHEBI:35221 antimetabolite
CHEBI has role CHEBI:35679 hypolipidemic agent
CHEBI has role CHEBI:35821 hypocholesteremic agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypercholesterolemia indication 13644009
Hyperlipidemia indication 55822004 DOID:1168
Familial hypercholesterolemia - homozygous indication 238078005
Familial hypercholesterolemia - heterozygous indication 238079002
Sitosterolemia indication 238104009 DOID:0090019
Mixed hyperlipidemia indication 267434003
Alopecia areata off-label use 68225006 DOID:986
Alcoholism contraindication 7200002
Acute nephropathy contraindication 58574008
Disorder of muscle contraindication 129565002 DOID:423
Liver function tests abnormal contraindication 166603001
Acute pancreatitis contraindication 197456007 DOID:2913
Hemorrhagic cerebral infarction contraindication 230706003
Disease of liver contraindication 235856003 DOID:409
Rhabdomyolysis contraindication 240131006
Pregnancy, function contraindication 289908002
Surgical procedure contraindication 387713003
Breastfeeding (mother) contraindication 413712001
SLCO1B1 Gene Variant for OATP1B1 Transporter Affecting Hepatic Clearance contraindication
Myopathy related to SLCO1B1 Gene Variant contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.48 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
180MG;10MG NEXLIZET ESPERION THERAPS INC N211617 Feb. 26, 2020 RX TABLET ORAL Feb. 26, 2023 NEW PRODUCT
180MG;10MG NEXLIZET ESPERION THERAPS INC N211617 Feb. 26, 2020 RX TABLET ORAL Feb. 21, 2025 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Niemann-Pick C1-like protein 1 Membrane other ANTAGONIST Kd 6.66 IUPHAR CHEMBL
Niemann-Pick C1-like protein 1 Unclassified Ki 6.70 CHEMBL

External reference:

IDSource
4021366 VUID
N0000148785 NUI
D01966 KEGG_DRUG
4021366 VANDF
C1707992 UMLSCUI
CHEBI:49040 CHEBI
CHEMBL1138 ChEMBL_ID
DB00973 DRUGBANK_ID
D000069438 MESH_DESCRIPTOR_UI
150311 PUBCHEM_CID
6816 IUPHAR_LIGAND_ID
8010 INN_ID
EOR26LQQ24 UNII
341248 RXNORM
17026 MMSL
229065 MMSL
45364 MMSL
d04824 MMSL
009817 NDDF
408041006 SNOMEDCT_US
409149001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ezetimibe HUMAN PRESCRIPTION DRUG LABEL 1 0591-3713 TABLET 10 mg ORAL ANDA 26 sections
Ezetimibe HUMAN PRESCRIPTION DRUG LABEL 1 0615-8300 TABLET 10 mg ORAL ANDA 27 sections
Ezetimibe HUMAN PRESCRIPTION DRUG LABEL 1 0781-5690 TABLET 10 mg ORAL ANDA 27 sections
Ezetimibe HUMAN PRESCRIPTION DRUG LABEL 1 0904-6664 TABLET 10 mg ORAL ANDA 28 sections
Ezetimibe HUMAN PRESCRIPTION DRUG LABEL 1 0904-7103 TABLET 10 mg ORAL ANDA 26 sections
ezetimibe and simvastatin HUMAN PRESCRIPTION DRUG LABEL 2 16714-778 TABLET 10 mg ORAL ANDA 28 sections
ezetimibe and simvastatin HUMAN PRESCRIPTION DRUG LABEL 2 16714-779 TABLET 10 mg ORAL ANDA 28 sections
ezetimibe and simvastatin HUMAN PRESCRIPTION DRUG LABEL 2 16714-780 TABLET 10 mg ORAL ANDA 28 sections
ezetimibe and simvastatin HUMAN PRESCRIPTION DRUG LABEL 2 16714-781 TABLET 10 mg ORAL ANDA 28 sections
Ezetimibe Human Prescription Drug Label 1 16714-813 TABLET 10 mg ORAL ANDA 28 sections
EZETIMIBE HUMAN PRESCRIPTION DRUG LABEL 1 16729-433 TABLET 10 mg ORAL ANDA 29 sections
VYTORIN HUMAN PRESCRIPTION DRUG LABEL 2 21695-325 TABLET 10 mg ORAL NDA 28 sections
VYTORIN HUMAN PRESCRIPTION DRUG LABEL 2 21695-339 TABLET 10 mg ORAL NDA 28 sections
Zetia HUMAN PRESCRIPTION DRUG LABEL 1 21695-778 TABLET 10 mg ORAL NDA 29 sections
VYTORIN HUMAN PRESCRIPTION DRUG LABEL 2 21695-827 TABLET 10 mg ORAL NDA 28 sections
Ezetimibe and Simvastatin HUMAN PRESCRIPTION DRUG LABEL 2 43598-742 TABLET 10 mg ORAL ANDA 28 sections
Ezetimibe and Simvastatin HUMAN PRESCRIPTION DRUG LABEL 2 43598-743 TABLET 10 mg ORAL ANDA 28 sections
Ezetimibe and Simvastatin HUMAN PRESCRIPTION DRUG LABEL 2 43598-744 TABLET 10 mg ORAL ANDA 28 sections
Ezetimibe and Simvastatin HUMAN PRESCRIPTION DRUG LABEL 2 43598-745 TABLET 10 mg ORAL ANDA 28 sections
Ezetimibe and Simvastatin HUMAN PRESCRIPTION DRUG LABEL 2 45963-565 TABLET 10 mg ORAL ANDA 28 sections
Ezetimibe and Simvastatin HUMAN PRESCRIPTION DRUG LABEL 2 45963-566 TABLET 10 mg ORAL ANDA 28 sections
Ezetimibe and Simvastatin HUMAN PRESCRIPTION DRUG LABEL 2 45963-567 TABLET 10 mg ORAL ANDA 28 sections
Ezetimibe and Simvastatin HUMAN PRESCRIPTION DRUG LABEL 2 45963-568 TABLET 10 mg ORAL ANDA 28 sections
Ezetimibe HUMAN PRESCRIPTION DRUG LABEL 1 50090-3087 TABLET 10 mg ORAL ANDA 26 sections
Ezetimibe Human Prescription Drug Label 1 50090-3657 TABLET 10 mg ORAL ANDA 27 sections
Ezetimibe and Simvastatin HUMAN PRESCRIPTION DRUG LABEL 2 50090-3984 TABLET 10 mg ORAL ANDA 27 sections
Ezetimibe and Simvastatin Human Prescription Drug Label 2 50090-4772 TABLET 10 mg ORAL ANDA 27 sections
Ezetimibe HUMAN PRESCRIPTION DRUG LABEL 1 50228-379 TABLET 10 mg ORAL ANDA 29 sections
Ezetimibe HUMAN PRESCRIPTION DRUG LABEL 1 50268-298 TABLET 10 mg ORAL ANDA 26 sections
Ezetimibe and Simvastatin HUMAN PRESCRIPTION DRUG LABEL 2 51407-190 TABLET 10 mg ORAL ANDA 28 sections